Sangle Nikhil A, Taylor Shari L, Emond Mary J, Depot Michelle, Overholt Bergein F, Bronner Mary P
Department of Pathology, Schulich School of Medicine and London Health Sciences Centre, London, Ontario, Canada.
Miraca Life Sciences, Dallas, TX, USA.
Mod Pathol. 2015 Jun;28(6):758-65. doi: 10.1038/modpathol.2015.2. Epub 2015 Feb 13.
Numerous histological mimics of high-grade dysplasia in Barrett's esophagus predispose to overdiagnosis and potential serious mismanagement, including unnecessary esophagectomy. This study investigates the prevalence and sources of this problem. Biopsies from 485 patients diagnosed with Barrett's high-grade dysplasia were screened for a multi-institutional, international Barrett's endoscopic ablation trial. Screening included review of the original diagnostic slides and an additional protocol endoscopy with an extensive biopsy sampling. Observer variability by the study pathologists was assessed through two blinded diagnostic rounds on 437 biopsies from 26 random study endoscopies. Study diagnostic reassessments revealed significantly lower rates of high-grade dysplasia. Only 248 patients (51%) were confirmed to have high-grade dysplasia. The remaining patients had inflamed gastric cardia without Barrett's (n=18; 7%), Barrett's without dysplasia (n=35; 15%), indefinite change (n=61; 26%), low-grade dysplasia (n=79; 33%), adenocarcinoma (n=43; 18%), and other (n=1; <1%), yielding an alarming total of 194 or 40% of patients who were overdiagnosed with Barrett's high-grade dysplasia. Study pathologists achieved a high-level agreement (90% three-way inter-observer agreement per biopsy, Kappa value 0.77) for high-grade dysplasia. Confounding factors promoting overdiagnosis included Barrett's inflammatory atypia (n=182), atypia limited to the basal metaplastic glands (n=147), imprecise criteria for low grade neoplasia (n=102), tangential sectioning artifact (n=59), and reactive gastric cardiac mucosa (n=38). A total of 194 patients (40%) were overdiagnosed with Barrett's high-grade dysplasia, as affirmed by the extensive screening process and high-level study pathologist agreement. The multiple diagnostic pitfalls uncovered should help raise pathologists' awareness of this problem and improve diagnostic accuracy.
巴雷特食管中许多高级别异型增生的组织学模拟物易导致过度诊断和潜在的严重管理失误,包括不必要的食管切除术。本研究调查了该问题的发生率和根源。对485例诊断为巴雷特食管高级别异型增生的患者的活检样本进行筛查,用于一项多机构、国际性的巴雷特内镜消融试验。筛查包括复查原始诊断切片以及进行一次额外的协议内镜检查并进行广泛的活检取样。通过对来自26例随机研究内镜检查的437份活检样本进行两轮盲法诊断,评估研究病理学家之间的观察者变异性。研究诊断重新评估显示高级别异型增生的发生率显著降低。只有248例患者(51%)被确诊为高级别异型增生。其余患者有贲门胃黏膜炎症但无巴雷特食管(n = 18;占7%)、有巴雷特食管但无异型增生(n = 35;占15%)、不确定改变(n = 61;占26%)、低级别异型增生(n = 79;占33%)、腺癌(n = 43;占18%)以及其他情况(n = 1;<1%),令人震惊的是,共有194例患者(占40%)被过度诊断为巴雷特食管高级别异型增生。研究病理学家对高级别异型增生达成了高度一致(每份活检样本的三方观察者间一致性为90%,Kappa值为0.77)。促进过度诊断的混杂因素包括巴雷特食管的炎症性异型性(n = 182)、局限于基底化生腺体的异型性(n = 147)、低级别肿瘤形成的不精确标准(n = 102)、切线切片假象(n = 59)以及反应性贲门胃黏膜(n = 38)。经广泛筛查过程和研究病理学家的高度一致确认,共有194例患者(占40%)被过度诊断为巴雷特食管高级别异型增生。所发现的多个诊断陷阱应有助于提高病理学家对该问题的认识并提高诊断准确性。